Bioventus to Present at the Morgan Stanley Global Healthcare Conference
Get Alerts BVS Hot Sheet
Join SI Premium – FREE
DURHAM, N.C., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice-president and chief financial officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Wednesday, September 14, 2022, at 11:10 a.m. ET.
A live webcast of the fireside chat will be available on the “Investors” section of the Company’s website at www.bioventus.com and will be available for replay on that site following the event.
About BioventusBioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for pain treatment, restorative therapies and surgical solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com, and follow the Company on LinkedIn and Twitter. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.
Investor and Media Contact:Dave Crawford919-474-6787[email protected]
Source: Bioventus, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mesoblast Reports Substantial Revenue Growth to US$120M
- GotRot Calls Attention to Crawl Space Moisture Risks in Greater Seattle Homes Ahead of Rainy Season
- Georgia Power's contract with OpenAI approved; Latest approval part of portfolio of large-load contracts delivering approximately $950 million in annual savings beginning in 2029
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Morgan Stanley, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share